These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38122)

  • 1. Metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine dihydrochloride in rat urine.
    Beretta E; Cristina T; Ferrari P; Tuan G; Zerilli LF; Martinelli E
    Eur J Drug Metab Pharmacokinet; 1979; 4(1):29-33. PubMed ID: 38122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of three metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine. A new rearrangement of 3-[1-methylethyliden)hydrazino] derivative.
    Bellasio E; Campi A
    Farmaco Sci; 1978 Aug; 33(8):565-72. PubMed ID: 744255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and metabolism of 3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino] pyridazine dihydrochloride in man.
    Assandri A; Perazzi A; Buniva G; Pagani V
    Eur J Drug Metab Pharmacokinet; 1979; 4(2):75-82. PubMed ID: 488135
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparative study of the hemodynamic effects of single intravenous doses of 3-hydrazino-6-[N,N-bis-(2-hydroxyethyl)-amino]-pyridazine-dihydrochloride and hydralazine.
    De Ponti C; Bardi U; Marchetti M
    Arzneimittelforschung; 1976; 26(11):2089-92. PubMed ID: 1037254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats.
    Watanabe TX; Shiono K; Saito K; Sokabe H
    Jpn J Pharmacol; 1978 Jun; 28(3):413-22. PubMed ID: 702944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic oxidation of the pyrrole ring: structure and origin of some urinary metabolites of the anti-hypertensive pyrrolylpyridazinamine, mopidralazine. III: Studies with the 13C-labelled drug.
    Assandri A; Tarzia G; Bellasio E; Ciabatti R; Tuan G; Ferrari P; Zerilli L; Lanfranchi M; Pelizzi G
    Xenobiotica; 1987 May; 17(5):559-73. PubMed ID: 3604261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onthe pharmacology of 3-hydrazino-6-(N,N-bis(2-hydroxyethyl)amino)-pyridazine-dihydrochloride (L 6150).
    Baldoli E; Sardi A; Dezulian V; Capellini M; Bianchi G
    Arzneimittelforschung; 1973 Nov; 23(11):1591-5. PubMed ID: 4801666
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats.
    Kawashima K; Watanabe TX; Sokabe H
    Jpn J Pharmacol; 1980 Feb; 30(1):116-8. PubMed ID: 6995653
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of 3-hydrazine-6[N,N-bis(2-hydroxyethyl)-amino]-pyridazine dihydrochloride (L6150) on the general and cardiac haemodynamics of the intact dog.
    Maxwell GM
    Clin Exp Pharmacol Physiol; 1976; 3(4):343-8. PubMed ID: 975622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action of a new hypotensive agent: 3-hydrazino-6-(N,N-bis-(2-hydroxyethyl)-amino)-pyridazine chlorhydrate (L 6150)].
    Baldoli E; Sardi A; Caravaggi AM; Bianchi G
    Boll Chim Farm; 1972 Aug; 111(8):480-8. PubMed ID: 4647088
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biotransformation of pyridazines. 1. Pyridazine and 3-methylpyridazine].
    Borchert HH; Pfeifer S; Helbig B; Franke P; Heinisch G
    Pharmazie; 1989 Sep; 44(9):625-30. PubMed ID: 2608708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of new [1,2,4]triazolo[4,3-b]pyridazines. Part 12: Studies in the field of pyridazine compounds.
    Kosáry J; Kasztreiner E; Lázár A; Sóti M
    Pharmazie; 1983 Jun; 38(6):369-71. PubMed ID: 6611639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Derivatives of pyridazine. 5. Synthesis and antihypertensive activity of 6-phenyl-5-morpholinylmethyl-3-hydrazino pyridazines].
    Orallo F; Calleja JM; García Mera G; Raviña E
    Arch Farmacol Toxicol; 1985 Dec; 11(3):171-82. PubMed ID: 4096551
    [No Abstract]   [Full Text] [Related]  

  • 14. High-performance liquid chromatographic separation of cadralazine from its potential metabolites and degradation products. Quantitation of the drug in human plasma and urine.
    Crolla T; Santini F; Visconti M; Pifferi G
    J Chromatogr; 1984 Sep; 310(1):139-49. PubMed ID: 6501510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biotransformation of the trapidil (rocornal) derivative AR 12463 in the rat].
    Pfeifer S; Langner A; Grahlmann D; Franke P; Gründemann E; Tenor E
    Pharmazie; 1990 Jul; 45(8):609-14. PubMed ID: 2080211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new antihypertensive compound: 3 hydrazino-6- [(2-hydroxypropyl)methylamino] pyridazine dihydrochloride (ISF 2123).
    Dorigotti L; Rolandi R; Carpi C
    Pharmacol Res Commun; 1976 Jun; 8(3):295-308. PubMed ID: 17122
    [No Abstract]   [Full Text] [Related]  

  • 17. [Elimination of p-brom-hydrazino-pyridazine and of p-brom-phenyl-hydrazino-pyridazine from the body].
    Gafiţeanu E; Stefănescu E; Mocanu R; Petrovanu M
    Rev Med Chir Soc Med Nat Iasi; 1974; 78(3):703-6. PubMed ID: 4453699
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150.
    Maseri A; Pesola A; L'Abbate A; Contini C; Magini G
    J Int Med Res; 1976; 4(6):402-9. PubMed ID: 1027634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bicyclic 3-hydrazinopyridazines with antihypertensive action (author's transl)].
    Schenker E; Salzmann R
    Arzneimittelforschung; 1979; 29(12):1835-43. PubMed ID: 546422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term study of oxdralazine in hypertensive patients.
    Salvadeo A; Villa G; Segagni S; Criscuolo D
    Arzneimittelforschung; 1979; 29(11):1753-5. PubMed ID: 396926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.